Archive for the ‘Bartonella’ Category

Landmark Study: Vaccination is the Dominant Risk Factor For Autism

UPDATE:

Go here to listen to Nicolas Hulscher and Dr. Andrew Wakefield discuss the landmark autism report.

https://www.thefocalpoints.com/p/breaking-landmark-report-finds-vaccination?

BREAKING — Landmark Report Finds Vaccination Is the Dominant Risk Factor for Autism Spectrum Disorder

McCullough Foundation’s authoritative analysis of more than 300 studies provides the most comprehensive synthesis to date on the possible causes of autism.

Nicolas Hulscher, MPH
Oct 27, 2025

For decades, scientists have debated what drives the relentless rise in autism. Some have claimed it’s due to “increased screening” while others declare it’s anything but vaccines. Thousands of studies have explored genetic, environmental, and perinatal factors—but very few have ever examined vaccine and non-vaccine determinants together within a unified analytical framework.

Now, the landmark McCullough Foundation Report titled, Determinants of Autism Spectrum Disorder, provides the most comprehensive synthesis on the possible causes of autism to-date. Thanks to the tireless work of Nicolas Hulscher, MPH, John S. Leake, MA, Simon Troupe, MPH, Claire Rogers, MSPAS, PA-C, Kirstin Cosgrove, BM, CCRA, M. Nathaniel Mead, MSc, PhD, Bre Craven, PA-C, Mila Radetich, Andrew Wakefield, MBBS, and Peter A. McCullough, MD, MPH — and support from the Bia-Echo Foundation — this historic effort was made possible.

Our report represents a major breakthrough through the iron grip of censorship imposed by the Bio-Pharmaceutical Complex on the issue of vaccination and autism. It also marks Dr. Andrew Wakefield’s first major return to the scientific literature in years—after enduring years of irrational attacks from the vaccine cartel.

By systematically integrating more than 300 studies across epidemiologic, clinical, mechanistic, and molecular domains, our team delivers the most extensive mapping yet of autism’s multifactorial origins and opens a new line of inquiry into how environmental and iatrogenic exposures intersect with genetic susceptibility.

By evaluating all known risk factors side by side, this analysis uniquely clarifies the relative contribution of vaccination compared to genetic and environmental domains. No prior review has attempted this integrative scope without excluding positive vaccine-association studies or unvaccinated controls—an essential step in determining whether vaccines truly play a role in autism risk, and if so, how significant that role is within the broader causal landscape.

Here’s what we found as described in the Abstract:

Introduction: Autism spectrum disorder (ASD) is now estimated to affect more than 1 in 31 children in the United States, with prevalence rising sharply over the past two decades and posing an increasing burden to families and public health systems. Most of the literature on ASD characterizes it as a complex neurodevelopmental condition shaped by multiple determinants, including genetic liability, immune dysregulation, perinatal stressors, and environmental toxicants. Since 1996, the possible role of childhood vaccination has also been discussed and debated. This review synthesizes the full range of evidence to clarify both vaccine-related and non-vaccine contributors to ASD risk.

Methods: We comprehensively examined epidemiologic, clinical, and mechanistic studies evaluating potential ASD risk factors, assessing outcomes, exposure quantification, strength and independence of associations, temporal relationships, internal and external validity, overall cohesiveness, and biological plausibility.

Results: We found potential determinants of new onset ASD before the age of 9 years old to include: older parents (>35 years mother, >40 years father), premature delivery before 37 weeks of gestation, common genetic variants, siblings with autism, maternal immune activation, in utero drug exposure, environmental toxicants, gut-brain axis alterations and combination routine childhood vaccination. These diverse genetic, environmental, and iatrogenic factors appear to intersect through shared pathways of immune dysregulation, mitochondrial dysfunction, and neuroinflammation, culminating in neurodevelopmental injury and regression in susceptible children. Of 136 studies examining childhood vaccines or their excipients, 29 found neutral risks or no association, while 107 inferred a possible link between immunization or vaccine components and ASD or other neurodevelopmental disorders (NDDs), based on findings spanning epidemiologic, clinical, mechanistic, neuropathologic, and case-report evidence of developmental regression. 12 studies comparing routinely immunized versus completely unvaccinated children or young adults consistently demonstrated superior overall health outcomes among the unvaccinated, including significantly lower risks of chronic medical problems and neuropsychiatric disorders such as ASD. The neutral association papers were undermined by absence of a genuinely unvaccinated control group—with partial or unverified immunization even among those classified as unvaccinated—alongside registry misclassification, ecological confounding, and averaged estimates that obscure effects within vulnerable subgroups. Only a few case–control studies verified vaccination through medical records or parent-held cards, and none performed independent clinical assessments of the children for ASD. In contrast, the positive association studies found both population signals (ecologic, cohort, case–control, dose–response, and temporal clustering) and mechanistic findings converging on biologic plausibility: antigen, preservative, and adjuvant (ethyl mercury and aluminum) induced mitochondrial and neuroimmune dysfunction, central nervous system injury, and resultant incipient phenotypic expression of ASD. Clustered vaccine dosing and earlier timing of exposure during critical neurodevelopmental windows appeared to increase the risk of ASD. These findings parallel strong, consistent increases in cumulative vaccine exposure during early childhood and the reported prevalence of autism across successive birth cohorts. To date, no study has evaluated the safety of the entire cumulative pediatric vaccine schedule for neurodevelopmental outcomes through age 9 or 18 years. Nearly all existing research has focused on a narrow subset of individual vaccines or components—primarily MMR, thimerosal-containing, or aluminum-adjuvanted products—meaning that only a small fraction of total childhood vaccine exposure has ever been assessed for associations with ASD or other NDDs.

Conclusion: The totality of evidence supports a multifactorial model of ASD in which genetic predisposition, neuroimmune biology, environmental toxicants, perinatal stressors, and iatrogenic exposures converge to produce the phenotype of a post-encephalitic state. Combination and early-timed routine childhood vaccination constitutes the most significant modifiable risk factor for ASD, supported by convergent mechanistic, clinical, and epidemiologic findings, and characterized by intensified use, the clustering of multiple doses during critical neurodevelopmental windows, and the lack of research on the cumulative safety of the full pediatric schedule. As ASD prevalence continues to rise at an unprecedented pace, clarifying the risks associated with cumulative vaccine dosing and timing remains an urgent public health priority.

(See link for article)
__________________
For more:

Category:

Autism, Bartonella, Lyme, vaccines

When Lyme Stopped My Childhood

https://magazine.publichealth.jhu.edu/2025/when-lyme-stopped-my-childhood

When Lyme Stopped My Childhood

The tickborne disease stole years of my life, but it also revealed my superpower.
By Kristen Johansson
10/10/25

I was 11 when my body changed. First came the fevers and headaches. Then tremors. Then seizures.  

Joint pain and frequent injuries meant sports disappeared. Brain fog and panic attacks meant school did too. By eighth grade in 2019, I was absent from most everything that had once defined me. I went from being a straight-A, four-sport student with a thriving social life to spending Thanksgiving and Christmas in the hospital. 

After two and a half years of severe illness, 30 doctors, and multiple misdiagnoses, I finally had an answer in 2020: Lyme disease, bartonellosis, and babesiosis. The diagnoses of three tickborne diseases brought some hope, but names alone couldn’t bring relief. My immune system was so depleted that a bout of mononucleosis that year broke me. 

I lost the ability to read. To walk. To talk. To eat. Even my short-term memory failed. My body stopped producing blood, making testing impossible. The hospital sent me home and told my family to prepare for me to die. 

But immunotherapy and aggressive treatment with long-term antibiotics, countless supplements, and daily injections gave me back pieces of myself. The first time I could read again, I clutched the words like they were oxygen. 

More than novels or school assignments, it was research that became my anchor. I became a detective, immersing myself in a cold case file of my old lab results and new studies, searching for answers that puzzled even my doctors. My days blurred into hours of YouTube lectures and Q&As from experts—each lesson a clue helping me to decipher how an infection could ripple through so many parts of me. When my liver could no longer withstand the harsh drugs I’d been taking for years, I researched alternatives, drawing on pioneering studies by Johns Hopkins researchers. I brought printed copies of these articles on herbal therapies to my doctors, ultimately shaping the protocols that led me to remission. (See link for article)

_______________

**Comment**

Completely relatable.

Similar stories only the names have been changed….

For more:

Category:

Babesia, Bartonella, Lyme

Lyme Treatment Explained: Co-infections & Complex Cases

https://imahealth.substack.com/p/lyme-treatment-explained-co-infections

Lyme Treatment Explained: Co-infections and Complex Cases

IMA Senior Fellow Dr. Yusuf (JP) Saleeby hosts Part 3 in a series of Weekly Webinars on diagnosing and treating Lyme Disease.
Independent Medical Alliance's avatar
Independent Medical Alliance
Jun 28, 2025

Speakers: Dr. Yusuf (JP) Saleeby, Dr. Tom Moorcroft, Chris Jackman, FNP

Lyme disease is notoriously difficult to treat, but it’s even more complex than most realize. That’s because Lyme doesn’t always travel alone. Associated tick-borne co-infections like Bartonella and Babesia can mimic or mask Lyme symptoms, requiring different treatments to resolve. This reality turns Lyme treatment into a winding, uncertain road for patients and providers alike.

Luckily, we’ve enlisted some of the world’s top experts in Lyme and chronic disease to help demystify this debilitating condition. Join IMA Senior Fellow Dr. JP Saleeby as he hosts a practical conversation with Lyme specialist Dr. Tom Moorcroft and integrative nurse practitioner Chris Jackman. Together, they’ll break down what makes Lyme so persistent, how co-infections complicate recovery, and what successful treatment protocols can look like in the real world.

This is the third installment in IMA’s Lyme Disease series—an essential session for patients, practitioners, and anyone trying to make sense of this often-misunderstood chronic condition. Catch up with the previous episodes here:  (See link for article and video seminars)

More from IMA on Lyme:

Check out our ever-expanding Lyme Library for more:

_________________

For more:

One things for sure: a multi-drug combination is required for this.  Doctors who still prescribe ONE drug for this are hopelessly in the dark.  I would even add that ONE drug for an acute case isn’t enough and that tinidazole should be pulsed along with daily doxycycyline or minocycline until symptoms are completely gone.  I would also recommend blood ozone – the stronger the better – EBOO preferably.  If other coinfection symptoms arise – then the drugs that are effective for them should be layered in.  This is no joke, and the days of treating this passively are long gone.  Wake up doctors and do the right thing!

Category:

Babesia, Bartonella, Lyme, Treatment

Bartonella and Babesia Detected in Patients With Chronic Illness

https://news.ncsu.edu/2024/07/bartonella-and-babesia-co-infection-detected-in-patients-with-chronic-illness/

Bartonella and Babesia Co-Infection Detected in Patients with Chronic Illness

July 16, 2024  
For Immediate Release
Tracey Peake
Edward Breitschwerdt

A small pilot study has found evidence of human co-infections from Bartonella and Babesia odocoilei, a protozoal tick-borne infection primarily found in deer, moose and other cervids. The co-infections were detected in six of seven patients suffering from chronic, non-specific illness, who were enrolled in a Bartonella study at North Carolina State University. The work presents some of the first definitive DNA evidence of this strain of Babesia infection in humans, and could impact treatments for patients with Bartonella, Borrelia or Babesia infections.

Bartonella are a group of vector-borne bacteria transmitted primarily via arthropods like fleas, lice and potentially ticks, but also by the animals that harbor them. There are at least 45 different known Bartonella species, of which 18 have been found to infect humans. Improved methods for detecting Bartonella infection in animals and humans have led to the diagnosis of bartonelloses in patients with a host of chronic illnesses, as well as in some patients with psychiatric symptoms.

In the U.S., the main Babesia species that infect humans are B. microti, B. duncani and B. divergens-like. Transmission occurs mainly by tick bite, but there are reports of transmission by transfusion of contaminated blood, organ transplantation and transplacental transmission. In addition to asymptomatic infection, babesiosis can be associated with non-specific symptoms such as fever, chills and night sweats, or with severe, life-threatening hemolytic anemia.

Babesia and Bartonella are often suspected as co-infections with Lyme disease, caused by the bacterium Borrelia burgdorferi.

“Doctors who work with Lyme patients often suspect co-infection with Babesia most often based on serology data and symptoms,” says Edward Breitschwerdt, Melanie S. Steele Distinguished Professor of Internal Medicine at NC State’s College of Veterinary Medicine and corresponding author of a paper describing the work. “So we decided to test for potential co-infections with this subset of our Bartonella study participants.”

The seven patients in the pilot study were already enrolled in a larger study aimed at detecting Bartonella in the blood of people with chronic illness and extensive animal contact. The participants’ ages ranged from two-and-a-half to 62 years old. Four were veterinary workers, one was a student and veterinary technician, one was a veterinarian’s daughter and one was a pre-school aged child. All submitted blood and tissue samples for testing.

Using digital droplet PCR testing, which identifies pathogens by their DNA sequences, the researchers discovered that all seven participants were infected with Babesia odocoilei, and that six of the seven were co-infected with at least one, and sometimes two or more, species of Bartonella.

“We were surprised by these findings for several reasons,” Breitschwerdt says. “First, this strain of Babesia – B. odocoilei – isn’t currently considered a cause of human infection. Second, these patients reside in locations around the U.S. and in Mexico, so the distribution may be geographically widespread. Finally, we were able to identify these seven infected individuals within a one-year time period, suggesting that this may be a more prevalent infection than currently appreciated.”

The findings could have implications for how patients with symptoms of vector-borne illnesses such as Lyme, babesiosis, or bartonellosis are tested and treated.

“The main symptom associated with babesiosis is acute, severe hemolytic anemia. None of these patients reported any such illness, a factor that could limit a doctor’s decision to test for Babesia infection,” Breitschwerdt says.

“This study primarily focused on patients with chronic illnesses and suspected bartonelloses. Most often, doctors don’t look for Babesia in these patients, but we now have good evidence that people can be infected by this organism, evidence that should be pursued in larger studies. Physicians who treat Lyme disease have often suspected co-infections with these pathogens, and it looks like their suspicions are correct, at least in a subset of patients.”

“We are committed to providing the best vector borne infectious disease testing results possible,” says Ricardo Maggi, research professor at NC State and first author of the study. “The cases presented in this manuscript reflect our team’s efforts to develop better approaches and diagnostic tools that can give answers to both patients and their doctors.”

The study appears in Parasites and Vectors and was supported by NC State’s Bartonella/Vector-Borne Diseases Research Fund and the Steven & Alexandra Cohen Foundation. NC State Ph.D. student Charlotte Moore, São Paulo State University Ph.D. student Ana Cláudia Calchi, and NC State research specialist Emily Kingston also contributed to the work.

For more:

Category:

Babesia, Bartonella, research

The Three Bs – Borrelia, What, and What? Co-infections & Chronic Illness

https://www.lymedisease.org/the-three-bs-borrelia-what/

The three Bs – Borrelia, What, and What? Co-infections and chronic illness

By Nicole Bell, Galaxy Diagnostics CEO

3/10/25

While many people in the Lyme community are familiar with the three Bs – Borrelia, Bartonella, and Babesia – most people outside the community look confused when I mention these top flea and tick-borne pathogens. I understand their puzzled looks because back in 2017, I was confused too.

Even after my husband, Russ, was diagnosed with these three stealthy invaders, I focused all my research on Borrelia, the bacteria causing Lyme disease.

It ended up taking a tragic journey followed by years of studying the research to gain an appreciation for the complexities of all three pathogens – and that research is still unfolding.

In complex cases, co-infections are the rule, not the exception.

The first thing to understand when considering the three Bs, is that in complex cases, co-infections are common. In a survey of over 3,000 chronic Lyme disease patients published by LymeDisease.org, over 50% had co-infections, and 30% had two or more co-infections. Babesia and Bartonella top the co-infection list, each presenting in about 30% of chronic Lyme cases.

Source: About Lyme Disease Co-infections, LymeDisease.org

The second thing to understand about these pathogens is that calling them “Lyme co-infections” is misleading. All these pathogens – the other Bs and beyond – can be present without a Borrelia  infection (past or present).

The problem is that many doctors don’t have these invaders on their differential – and it’s easy for a pathogen to be considered rare if you never test for it. 

Rare disease? Or inadequate testing and data?

To understand the true prevalence of these pathogens, we need to dig into the details of each pathogen and how we count and test for them. For example, before 2013, Lyme incidence in the U.S. was estimated to be approximately 30,000 cases per year. Then, in 2013, the CDC looked at clinical records, laboratory reports, and public surveys and increased this estimate 10-fold.

In 2021, an analysis of insurance records increased the estimates again, and current data shows that approximately 500,000 Americans are diagnosed and treated annually. And since the standard of care test for Lyme leading to diagnosis and treatment is 40-60% accurate, even this number is likely underestimating the extent of the problem.

So, the question looms – what is the prevalence of the other two Bs? Are they destined for a similar exponential increase as we dig into the data? Emerging research points to yes.

Bartonella – The Hidden Pandemic

Bartonella is a genus of gram-negative bacteria that can infect humans and a wide range of animals. Googling the bacteria shows that it is the pathogen causing cat scratch disease or CSD, an acute form of the infection. But like Lyme, this pathogen has been associated with complex chronic conditions spanning multiple body systems, including the joints, eyes, heart, and brain.

Lyme disease has made people fearful of ticks, but Bartonella can be transmitted by a long list of biting insects – or vectors – including fleas, body lice, sand flies, and even spiders. Also, an underappreciated risk factor for bartonellosis is animal exposure, particularly exposure to cats, which are natural reservoirs of the bacteria.

In a study of veterinary workers, 44% were positive for Bartonella antibodies, and 28% had DNA of the pathogen detected directly from their blood. With approximately 66% of U.S. households owning at least one pet, the pathogen has the potential to be more widespread than generally thought.

Dr. Ed Breitschwerdt from North Carolina State University’s veterinary school has studied Bartonella since the 1990s. The advanced testing methods developed in his lab by collaborator Dr. Ricardo Maggi have uncovered key links between the pathogen and complex illnesses, such as arthritis, chronic fatigue, and fibromyalgia.

Neuropsychiatric conditions

Recently, using innovations in advanced PCR technology, the lab has made groundbreaking discoveries linking Bartonella and neuropsychiatric conditions, such as schizophrenia.

The investigation into schizophrenia started the way many discoveries in medicine do, with one case. A 14-year-old boy – who we will call Michael – suffered from sudden onset psychosis and received a formal diagnosis of schizophrenia. Michael was referred to Dr. B’s lab because he had marks on his skin, called striae, consistent with a Bartonella infection.

Dr. B and his team used their advanced test methods to confirm that Michael was infected with Bartonella. Upon treatment with the appropriate antibiotics, his symptoms evaporated.

The case inspired Dr. Breitschwerdt to consider a hypothesis – what if other patients were experiencing psychosis because of a Bartonella infection? Bartonella can cross the blood-brain barrier and infect endothelial cells, contributing to neuroinflammation.

The hypothesis had merit. His lab partnered with the University of North Carolina to test 17 schizophrenia patients. Sixty-five percent of those patients tested PCR positive for the pathogen, compared to 8% in healthy controls.

A subsequent study with Columbia University on over 100 patients found that people affected with psychosis were over three times more likely to have direct evidence of Bartonella in their blood than unaffected controls.

PANS

And schizophrenia isn’t the only neuropsychiatric condition linked to the pathogen. Pediatric patients with Bartonella infections have been reported to develop Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) and symptoms like anxiety, obsessive-compulsive disorder, and cognitive dysfunction. Case studies have shown improvement in neuropsychiatric symptoms following treatment of the underlying infections.

With over 3 million Americans battling schizophrenia and 1 in 200 children in the U.S. affected by PANS, Bartonella may emerge as the great hidden pandemic.

Babesia – the tip of the iceberg

Babesia is a tick-borne parasitic infection, often touted as similar to malaria, because both parasites infect and replicate within red blood cells and can cause fever, chills, sweats, headache, muscle aches, fatigue, and hemolytic anemia.

Researching Babesia on the CDC Website shows that under 2000 cases were reported nationwide in 2020. The CDC notes that most Babesia cases in the U.S. are caused by Babesia microti, with occasional cases caused by other Babesia species.

Using the same advanced PCR technology that drove clinical discovery in Bartonella, Dr. B and his team turned their attention to Babesia. They found that what we “know” about Babesia may only be the tip of the iceberg.

In 82 individuals the lab was studying for Bartonella infection, 22 (27%) were also infected with Babesia. Furthermore, the top Babesia species identified was not Babesia microti, as expected from CDC data, but rather Babesia divergens (considered rare in the U.S.) and then Babesia odocoilei (considered rare in humans).

Before Dr. B’s work, only a handful of case reports in the U.S. have ever been reported for Babesia divergens. Their best-in-class assay turned up 12 new cases in a group that wasn’t even targeted for Babesia studies.

Dr. B’s team also recently published a paper where an entire family – all five members and one of their dogs – tested positive for a Babesia-divergens-like species. Similar new case discoveries have been made for Babesia odocoilei. His work poses the question – are the pathogens really rare, or are we just not testing for them properly?

Genus versus species – why it matters

Genus and species are terms commonly used by microbiologists, but when I first entered the world of tick-borne disease, I didn’t fully understand their significance. The “genus” is akin to a family name, grouping related individuals – think Hatfields and McCoys. The “species” is like the first name, identifying a specific individual in the family.

Translating this to Lyme disease, Borrelia is the genus or family name, and Borrelia burgdorferi is the species name identifying the particular pathogen.

So why does it matter? The current commercial test methods for all three Bs generally use serology or antibody testing. These assays measure antibodies created by the host’s immune response to the pathogen. The problem is that antibodies react to proteins on the surface of the pathogen, and these proteins can vary depending on the particular species.

In other words, the patriarch of the Hatfield family, Anderson Hatfield, looked and dressed differently than his son Cap Hatfield. Thus, sending out a warrant and a picture of Anderson is unlikely to lead to Cap’s arrest.

Antibody testing is similar, and testing for Babesia microti, may not accurately diagnose a case of Babesia odocoilei or Babesia divergens. There are over 100 known Babesia species, with 15 of those confirmed in human cases.

There are over 50 species of Bartonella, at least 20 of which have been documented to infect humans and other mammalian hosts. Dr. B’s research and testing technology is redefining what we know about these pathogens. And until these tests are launched commercially, millions have the potential to be misdiagnosed.

Direct Detection for BBB is Launching at Galaxy Diagnostics

Fortunately, Galaxy Diagnostics was founded by Dr. Breitschwerdt, Dr. Maggi, and Dr. Amanda Elam to bring these diagnostic advancements to market. This month, Galaxy is launching its digital PCR, direct detection assay for BBB.

This assay has been instrumental in driving clinical discovery in Dr. B’s lab and will now be commercially available to practitioners. Top features of the assay include:

  • Genus level detection, detecting each pathogen regardless of species.
  • Ultra-sensitive, digital PCR, which increases detectability for low abundance pathogens.
  • Multiplexed detection to provide three results in a single test.

The BBB assay is a blood-based assay that detects the DNA of each pathogen. The approach has previously been used only in a research setting, but the team at Galaxy has now validated the assay for commercial use.

Bartonella and Babesia – but what about Borrelia?

The BBB assay is a blood-based approach, and it is essential to note that blood is NOT the best matrix for Lyme Borrelia, as I have discussed previously.

Galaxy recommends its urine antigen test for Lyme since the concentrations of Lyme Borrelia are so low in the blood that a blood draw is unlikely to capture the pathogen in the test tube. And no matter how sensitive the technique is, if the pathogen isn’t in the tube, there is no way to detect it.

So then, why is Borrelia included in the BBB assay? The answer goes back to the genus versus species issue. While the species associated with Lyme Borrelia often hide in tissues and don’t free-circulate in high copy numbers in blood, the species associated with Relapsing Fever Borrelia do replicate to high numbers in the blood.

As a result, combining the BBB assay with Galaxy’s Nanotrap urine antigen test for Lyme provides optimal coverage for the top flea and tick-borne infections at the genus level.

Coming Full Circle – Avoiding Cases like Russ

After my husband Russ passed, the engineer in me knew there had to be better options. I immersed myself in the research and found Dr. B’s published peer-reviewed results. I introduced myself to the Galaxy team, and as I dug in, I became even more convinced that their technology would provide the clarity I craved as a caregiver.

In June 2024, I became Galaxy’s CEO to bring these advanced testing techniques to a broader market. We crystallized our mission to provide a new standard of care for diagnosing these devastating flea and tick-borne diseases. With the commercial launch of the BBB assay, we are one step closer to that goal. I know that Russ is watching – and smiling.

Nicole Bell, CEO of Galaxy Diagnostics, is also the author of What Lurks in the Woods and The State of Lyme Disease Research. 

For more:

Category:

Babesia, Bartonella, Lyme, PANS, Testing, Ticks, Treatment